← All Signals

🏥 FDA: Ascend Laboratories, LLC — Class II

healthcarebearishSource: FDA
75%Confidence
0Views
FDASource
2026-05-25Date

Summary

Ascend Laboratories' recall of metoprolol tablets for failed dissolution specifications may disrupt hypertension treatment supply chains and damage distributor relationships. The issue originating from Alkem Laboratories in India raises concerns about manufacturing quality controls.

Actionable: Assess exposure to Ascend Laboratories and Alkem Laboratories; diversify holdings in generic drug manufacturers with robust quality records.

AI Confidence: 75%

Data Points

firmAscend Laboratories, LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productAscend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distrib

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now